Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours.
de Jonge
M J A
MJ
Department of Medical Oncology, Erasmus Medical Center/Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. m.dejonge@erasmusmc.nl
Kaye
S
S
Verweij
J
J
Brock
C
C
Reade
S
S
Scurr
M
M
van Doorn
L
L
Verheij
C
C
Loos
W
W
Brindley
C
C
Mistry
P
P
Cooper
M
M
Judson
I
I
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D019540:Area Under Curve; D002851:Chromatography, High Pressure Liquid; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D010619:Phenazines / Q000493:pharmacokinetics* / Q000627:therapeutic use; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors
C446952:4-methoxybenzo(a)phenazine-11-carboxylic acid (2-(dimethylamino)-1-methylethyl)amide; D004791:Enzyme Inhibitors; D010619:Phenazines; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors